Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 30, 2018

View Archived Issues

Cutting carb clutter could transform diabetes treatment

Patient enrollment ongoing in phase I study of EHP-101

Oncorus nominates lead clinical candidate

FF-10850, a novel liposomal topotecan with improved preclinical PK, safety and antitumor effects

Morphogen-IX names clinical candidate for PAH

miR 1249-5p identified as novel biomarker in NASH

New palbociclib-resistant luminal A breast cancer PDX model from a clinically resistant patient

New animal models of prostate cancer designed for immuno-oncology research

Relafalk approved by the European decentralized procedure for treatment of travelers' diarrhea

Pulmocide initiates phase II study of PC-945

BDP-9066 significantly increases survival and prevents radiation-induced infiltration of GBM in vivo

Phase I results reported for EBV-specific T-cell therapy in progressive multiple sclerosis

Takeda describes new BRD4 BD2 domain inhibitors

Transitional endoplasmic reticulum ATPase inhibitors identified at the University of Pittsburgh

Positive preliminary phase I data presented for TransCon CNP

The Warner Babcock Institute for Green Chemistry patents beta-amyloid inhibitors

Genetics of ADHD correlates with health risk behavior

KCNQ2/3 channel activators patented by Knopp Biosciences

Forge Therapeutics presents bacterial lpxC inhibitors

Phase III clinical study of Fycompa monotherapy meets primary endpoint

Takhzyro subcutaneous injection approved in Europe for the preventive treatment of HAE

Precedex approved for use in pediatric patients in Japan

Positive topline data presented from ENLIGHTEN-2 phase III study of ALKS-3831

Positive phase II data presented, initiation of phase III pemphigus program announced for PRN-1008

First patient enrolled in phase III study of JZP-258 for the treatment of idiopathic hypersomnia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...